Specific Area of Interest: 

Projects that will be considered for Pfizer support will focus on:

• Increasing the understanding of the mechanism of action, biological and clinical rationale for PARP inhibitor combinations as potential treatments for prostate cancer.
• PARP-inhibitor combinations with androgen receptor targeted therapies.
• The evolving paradigm of the potential treatment of mCRPC with future PARP-inhibitor combinations.
• Optimal therapy management for PARP-inhibitor combinations in prostate cancer.